Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma

Review

(1831) Views  (518) Full article downloads

Authors: Martina Lehnert, Heinz Ludwig, Niklas Zojer

Published Date July 2009 Volume 2009:2 Pages 199 - 208

DOI: http://dx.doi.org/10.2147/OTT.S3975

Martina Lehnert, Heinz Ludwig, Niklas Zojer

1st Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria

Abstract: The development of radiolabeled antibodies against CD20 has facilitated targeted treatment of follicular lymphoma (FL). By using ⁹⁰Y-ibritumomab tiuxetan (Zevalin^®), a radionuclide (yttrium-90, linked by the chelator tiuxetan to the antibody ibritumomab) is brought into the vicinity of lymphoma cells. By the so-called cross-fire effect, this beta emitter has the capacity to destroy not only the lymphoma cells having bound the antibody, but also neighboring lymphoma cells. Currently this antibody is licensed in the European Union for use in relapsed or refractory FL. It is anticipated that this drug will also be approved for use as consolidation therapy after successful first-line treatment. Here we first will review the published literature supporting the use of ⁹⁰Y-ibritumomab tiuxetan in the aforementioned indications and emerging data showing applicability of ibritumomab tiuxetan as sole first-line therapy for FL, as well as in the transplant setting. Possible strategies of incorporating ibritumomab tiuxetan into the treatment algorithm of FL are discussed.

Keywords: follicular lymphoma, ⁹⁰Y-ibritumomab tiuxetan